Published in Am J Manag Care on December 01, 2006
The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev (2009) 1.09
Human papillomavirus: the usefulness of risk factors in determining who should get vaccinated. Rev Obstet Gynecol (2008) 0.89
Epidemiology of Malignant Cervical, Corpus Uteri and Ovarian Tumours - Current Data and Epidemiological Trends. Geburtshilfe Frauenheilkd (2013) 0.86
Distribution of human papillomavirus genotypes in sardinian patients with oral squamous cell carcinoma. Open Virol J (2010) 0.83
Potential opportunities to reduce cervical cancer by addressing risk factors other than HPV. J Gynecol Oncol (2013) 0.83
Molecular Mechanism and Potential Targets for Blocking HPV-Induced Lesion Development. J Oncol (2011) 0.80
Quantifying the decisional satisfaction to accept or reject the Human Papillomavirus (HPV) vaccine: a preference for cervical cancer prevention. PLoS One (2014) 0.79
Reproductive factors associated to human papillomavirus infection in Iranian woman. J Family Reprod Health (2013) 0.76
Risk of Human Papillomavirus (HPV) Infection and Cervical Neoplasia after Pregnancy. BMC Pregnancy Childbirth (2015) 0.76
Redox regulation of the actin cytoskeleton and its role in the vascular system. Free Radic Biol Med (2017) 0.75
Frequency of Human papillomavirus in women attending cervical cancer screening program in Chile. BMC Cancer (2017) 0.75
Characteristics of cervical disease among symptomatic women with histopathological sample at Hawassa University referral hospital, Southern Ethiopia. BMC Womens Health (2017) 0.75
Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med (2007) 9.53
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst (2012) 3.87
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
The epidemiology of genital human papillomavirus infection. Vaccine (2006) 3.28
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis (2012) 3.25
Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis (2011) 3.16
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine (2006) 2.95
Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol (2007) 2.90
The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev (2003) 2.52
Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol (2007) 2.49
Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev (2006) 2.39
Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med (2007) 2.35
Delays in diagnosis and treatment among children and adolescents with cancer in Canada. Pediatr Blood Cancer (2008) 1.98
HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis (2011) 1.95
Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis (2009) 1.89
Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med (2011) 1.89
Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst (2003) 1.84
Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer (2003) 1.78
Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis (2008) 1.72
Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine (2007) 1.71
Management of low-grade cervical lesions in young women. CMAJ (2005) 1.69
Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer (2010) 1.65
Assessing the gain in diagnostic performance when combining two diagnostic tests. Stat Med (2002) 1.65
Reproductive health of adolescent girls perinatally infected with HIV. Am J Public Health (2007) 1.53
Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol (2006) 1.53
Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res (2010) 1.50
Diagnosis delays in childhood cancer: a review. Cancer (2007) 1.44
Human papillomavirus infection and oral cancer: a case-control study in Montreal, Canada. Oral Oncol (2007) 1.34
Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev (2005) 1.32
Making prospective registration of observational research a reality. Sci Transl Med (2014) 1.31
Predictors of cervical coinfection with multiple human papillomavirus types. Cancer Epidemiol Biomarkers Prev (2003) 1.31
p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev (2004) 1.26
Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: the interface with social factors and service utilization. Addiction (2004) 1.26
Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer (2012) 1.23
Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. Int J Cancer (2006) 1.22
Human papillomavirus infections among couples in new sexual relationships. Epidemiology (2010) 1.20
Genital transmission of human papillomavirus in recently formed heterosexual couples. J Infect Dis (2011) 1.15
Prevalence and age distribution of human papillomavirus infection in a population of Inuit women in Nunavik, Quebec. Cancer Epidemiol Biomarkers Prev (2008) 1.14
Burden of disease, health indicators and challenges for epidemiology in North America. Int J Epidemiol (2012) 1.12
Report of the 2003 pan-Canadian forum on cervical cancer prevention and control. J Obstet Gynaecol Can (2004) 1.09
Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol (2013) 1.09
Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS One (2011) 1.07
A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer (2010) 1.07
Human papillomavirus type 33 polymorphisms and high-grade squamous intraepithelial lesions of the uterine cervix. J Infect Dis (2006) 1.07
Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix. J Clin Microbiol (2012) 1.05
Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women. Cancer Epidemiol Biomarkers Prev (2009) 1.03
Comprehensive control of human papillomavirus infections and related diseases. Vaccine (2013) 1.02
Dietary intake and risk of persistent human papillomavirus (HPV) infection: the Ludwig-McGill HPV Natural History Study. J Infect Dis (2003) 1.01
HLA polymorphisms and cervical human Papillomavirus infection in a cohort of Montreal University students. J Infect Dis (2007) 1.01
Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women. BMC Infect Dis (2010) 1.00
Influence of postoperative infectious complications on long-term survival of lung cancer patients: a population-based cohort study. J Thorac Oncol (2013) 1.00
Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol (2011) 0.99
Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine (2008) 0.98
Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. Vaccine (2013) 0.98
cobas 4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens. Expert Rev Mol Diagn (2013) 0.97
Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer (2013) 0.95
Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur J Cancer Prev (2006) 0.95
Lung cancer screening: review and performance comparison under different risk scenarios. Lung (2013) 0.94
Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine (2006) 0.94
The impact of anogenital warts on health-related quality of life: a 6-month prospective study. Sex Transm Dis (2011) 0.94
The psychosocial impact of an abnormal cervical smear result. Psychooncology (2011) 0.92
Recommendations for cervical cancer prevention in Latin America and the Caribbean. Vaccine (2008) 0.92
Human leukocyte antigen (HLA)-E and HLA-G polymorphisms in human papillomavirus infection susceptibility and persistence. Hum Immunol (2011) 0.92
Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era. Sex Health (2010) 0.92
Dry self-sampling versus provider-sampling of cervicovaginal specimens for human papillomavirus detection in the Inuit population of Nunavik, Quebec. J Med Screen (2012) 0.91
Interaction between polymorphisms of the human leukocyte antigen and HPV-16 variants on the risk of invasive cervical cancer. BMC Cancer (2008) 0.90
Determinants of human papillomavirus infection among Inuit women of northern Quebec, Canada. Sex Transm Dis (2010) 0.90
Use of the normalized absorbance ratio as an internal standardization approach to minimize measurement error in enzyme-linked immunosorbent assays for diagnosis of human papillomavirus infection. J Clin Microbiol (2010) 0.90
Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. Int J Cancer (2008) 0.90
The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia. Cancer Detect Prev (2005) 0.89
Human papillomavirus type 52 polymorphism and high-grade lesions of the uterine cervix. Int J Cancer (2012) 0.89
Innovations in understanding the biology of cervical cancer. Cancer (2003) 0.88
Epidemiology, natural history and risk factors for anal intraepithelial neoplasia. Sex Health (2012) 0.88
Polymorphism of the capsid L1 gene of human papillomavirus types 31, 33, and 35. J Med Virol (2010) 0.88
Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. Int J Cancer (2014) 0.88
A new generation of studies of human papillomavirus DNA testing in cervical cancer screening. J Natl Cancer Inst (2009) 0.86
Influence of partner's infection status on prevalent human papillomavirus among persons with a new sex partner. Sex Transm Dis (2010) 0.86
Awareness and knowledge about human papillomavirus among Inuit women in Nunavik, Quebec. J Community Health (2011) 0.86
Counterpoint: cervical cancer screening guidelines--approaching the golden age. Am J Epidemiol (2013) 0.86
Human papillomavirus type 16 viral load measurement as a predictor of infection clearance. J Gen Virol (2013) 0.86
Loss of quality of life associated with genital warts: baseline analyses from a prospective study. Sex Transm Infect (2011) 0.85
Prognostic significance of lymph node variables and human papillomavirus DNA in invasive vulvar carcinoma. Gynecol Oncol (2004) 0.85
Performance of an adipokine pathway-based multilocus genetic risk score for prostate cancer risk prediction. PLoS One (2012) 0.85
Associations between serum carotenoids and tocopherols and type-specific HPV persistence: the Ludwig-McGill cohort study. Int J Cancer (2007) 0.85
Comparison of human papillomavirus testing and cytology for cervical cancer screening in a primary health care setting in the Democratic Republic of the Congo. Gynecol Oncol (2011) 0.85
Persistent HPV infection and cervical cancer risk: is the scientific rationale for changing the screening paradigm enough? J Natl Cancer Inst (2010) 0.85
Predictors of preoperative delays before radical cystectomy for bladder cancer in Quebec, Canada: a population-based study. BJU Int (2014) 0.85
Determinants of delays in treatment initiation in children and adolescents diagnosed with leukemia or lymphoma in Canada. Int J Cancer (2010) 0.84
Advances in prevention of cervical cancer and other human papillomavirus-related diseases. Pediatr Infect Dis J (2006) 0.84
Toward a reduction of the global burden of cervical cancer. Am J Obstet Gynecol (2003) 0.84
What is the role of HPV typing in the United States now and in the next five years in a vaccinated population? Gynecol Oncol (2010) 0.84
Economic evaluation of strategies for managing women with equivocal cytological results in Brazil. Int J Cancer (2010) 0.84
Is HPV testing with cytological triage a more logical approach in cervical cancer screening? Lancet Oncol (2006) 0.83
Prevalence and determinants of high-risk human papillomavirus infection in women from a sub-Saharan African community. Sex Transm Dis (2011) 0.83